Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Morphosys
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Novartis
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Nurix
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Pharmacyclics
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Regeneron
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Sanofi
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    SeaGen
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Takeda
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    TG Therapeutics
    Topic: 
    honorarium/consulting
    Date added: 
    05/05/2023

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes